Estrogen Receptor Degrader Shows Promise in ER-Positive Breast Cancer
A new strategy in the treatment of estrogen receptor (ER) breast cancer may be in the form of an ER degrader. Like the antiestrogen tamoxifen (Soltamox, Nolvadex), this treatment also prevents estrogen from stimulating tumor growth.
TLR5 Genetic Variants May Help Predict Response to Entolimod
A specific genetic signature may predict how solid tumor cancer patients respond to the immunotherapeutic drug entolimod in terms of tumor shrinkage as well as potentials side effects from the drug.
TERT Gene Alterations Found in Bladder Cancer
An important discovery regarding the bladder cancer genome was announced during the American Association for Cancer Research (AACR) meeting in Philadelphia, held April 18-22, 2015.